From the National Institutes of Health (NIH) (March 17, 2020):
“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said NIAID Director Anthony S. Fauci, M.D. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”
The vaccine is called mRNA-1273 and was developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial.
A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today.
The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine.
On this week’s show, senior correspondent Jeffrey Mervis joins host Sarah Crespi to discuss a new National Institutes of Health (NIH) grant program that aims to encourage diversity at the level of university faculty with the long-range goal of increasing the diversity of NIH grant recipients.
The National Institutes of Health’s largest loan repayment program was conceived to help scientists pay off school debts without relying on industry funding. But a close examination of the program by investigative correspondent Charles Piller has revealed that many participants are taking money from the government to repay their loans, while at the same time taking payments from pharmaceutical companies. Piller joins Host Sarah Crespi to talk about the steps he took to uncover this double dipping and why ethicists say this a conflict of interest.